The stock may react negatively to declining quarterly net income and Q1 2026 loss guidance despite revenue growth, but could find support in the maintained full-year profitability outlook and upcoming clinical catalysts for alisertib in 2026.
Price Chart
Executive Summary
Puma Biotechnology reported fourth quarter and full year 2025 financial results with product revenue growth to $204.1 million (up from $195.2 million in 2024) and maintained profitability, though net income declined slightly year-over-year. The company provided 2026 guidance projecting a net loss in Q1 but profitability for the full year, while advancing its alisertib clinical trials with key data readouts expected in 2026.
Key Financial Metrics
Key Facts
- Product revenue increased to $204.1 million in 2025 from $195.2 million in 2024
- Full year 2025 GAAP net income was $31.1 million, flat compared to $30.3 million in 2024
- Fourth quarter 2025 GAAP net income declined to $13.4 million from $19.3 million in 2024
- 2026 guidance includes Q1 net loss of $8-10 million but full year net income of $10-13 million
- Company has $97.5 million in cash and marketable securities with reduced debt of $22.5 million
Financial Impact
Revenue increased by $8.9 million year-over-year while net income remained flat at $31.1 million despite a $6 million increase in R&D expenses to $62.1 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $204.1M | +4.6% |
| Royalty Revenue | $24.3M | -31.2% |
Risk Factors
- Declining quarterly profitability despite revenue growth
- Increased R&D spending could pressure margins
- Clinical trial results for alisertib may not meet expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-005869 |
| Document: pbyi20260204_8k.htm | 0001437749-26-005869 |
| Document: 0001437749-26-005869-index-headers.html | 0001437749-26-005869 |
| Document: 0001437749-26-005869-index.html | 0001437749-26-005869 |
| Document: 0001437749-26-005869.txt | 0001437749-26-005869 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13D/A | $9.81 | awaiting T+20 | — | $10.97 (+11.82%) |
Sep 16, 2026 5w ago | Insider Cluster | $9.52 $10.52 | ▼ −10.50% | ▼ −9.30% | $10.97 (−15.23%) |
Jul 8, 2026 15w ago | Insider Cluster | $7.90 $8.12 | ▲ +2.78% | ▲ +0.54% | $10.97 (+38.86%) |
Jul 6, 2026 16w ago | 144 | $7.96 $7.69 | ▼ −3.39% | ▼ −4.72% | $10.97 (+37.81%) |
Jun 15, 2026 19w ago | Insider Cluster | $7.17 $8.28 | ▲ +15.48% | ▲ +15.28% | $10.97 (+53.00%) |
Jun 12, 2026 19w ago | 144 | $7.33 $8.00 | ▲ +9.14% | ▲ +7.36% | $10.97 (+49.66%) |
Feb 26, 2026 34w ago | 8-K | $5.70 $6.08 | ▲ +6.67% | ▲ +14.22% | $10.97 (+92.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers